Have the challenges of creating an effective oral insulin finally been overcome?
Read More »Managing Editor, Diabetes in Control
SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes
Cardiovascular events decline for patients using which antidiabetic medication?
Read More »Using a Quality Initiative to Improve Population HbA1c Testing
Can improving diabetes care be as simple as ensuring patients receive regular testing?
Read More »Dulaglutide Provides CVD Protection with or without Metformin
Data from the REWIND trial suggest that dulaglutide has cardioprotective properties.
Read More »Research Highlights Combination Canagliflozin plus Liraglutide Effects on HBA1c
The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c.
Read More »Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Care of the elderly can be very challenging. Can adding yet another medication actually help?
Read More »The Risk of T2D in Children Using Selective Serotonin Reuptake Inhibitors
Is the risk as substantial as was initially reported?
Read More »Diabetes and Subsequent Weight Loss Linked to an Increased Risk of Pancreatic Cancer
The case for expanding screening for pancreatic cancer in those with new onset of diabetes and weight loss.
Read More »SGLT-2 Inhibitors and the Risk for Urosepsis
Are SGLT-2 inhibitors responsible for urosepsis or Fournier's gangrene?
Read More »The Relationship Between Aerobic Exercise Capacity and Cardiac Dysfunction In T2D
In type 2 diabetes patients, treating diastolic function and myocardial perfusion reserve could improve aerobic exercise capacity and prevent heart failure.
Read More »